<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthma - Evans, DJW - 2015 | Cochrane Library</title> <meta content="Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthma - Evans, DJW - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011437.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthma - Evans, DJW - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011437.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011437.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthma" name="citation_title"/> <meta content="David JW Evans" name="citation_author"/> <meta content="Royal Lancaster Infirmary" name="citation_author_institution"/> <meta content="d.evans1@lancaster.ac.uk" name="citation_author_email"/> <meta content="Kayleigh M Kew" name="citation_author"/> <meta content="St George's, University of London" name="citation_author_institution"/> <meta content="Debbie E Anderson" name="citation_author"/> <meta content="University of Strathclyde" name="citation_author_institution"/> <meta content="Anne C Boyter" name="citation_author"/> <meta content="University of Strathclyde" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD011437.pub2" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/07/21" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011437.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011437.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011437.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Inhalation; Adrenal Cortex Hormones [*administration &amp; dosage]; Anti‐Asthmatic Agents [administration &amp; dosage]; Asthma [*drug therapy]; Beclomethasone [administration &amp; dosage]; Cross‐Over Studies; Muscarinic Antagonists [*administration &amp; dosage]; Randomized Controlled Trials as Topic; Tiotropium Bromide [administration &amp; dosage]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011437.pub2&amp;doi=10.1002/14651858.CD011437.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011437.pub2&amp;doi=10.1002/14651858.CD011437.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011437.pub2&amp;doi=10.1002/14651858.CD011437.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011437.pub2&amp;doi=10.1002/14651858.CD011437.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011437.pub2&amp;doi=10.1002/14651858.CD011437.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011437.pub2&amp;doi=10.1002/14651858.CD011437.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011437.pub2&amp;doi=10.1002/14651858.CD011437.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011437.pub2&amp;doi=10.1002/14651858.CD011437.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011437.pub2&amp;doi=10.1002/14651858.CD011437.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011437.pub2&amp;doi=10.1002/14651858.CD011437.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011437.pub2&amp;doi=10.1002/14651858.CD011437.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011437.pub2&amp;doi=10.1002/14651858.CD011437.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011437.pub2&amp;doi=10.1002/14651858.CD011437.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011437.pub2&amp;doi=10.1002/14651858.CD011437.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011437.pub2&amp;doi=10.1002/14651858.CD011437.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011437.pub2&amp;doi=10.1002/14651858.CD011437.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011437.pub2&amp;doi=10.1002/14651858.CD011437.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011437.pub2&amp;doi=10.1002/14651858.CD011437.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011437.pub2&amp;doi=10.1002/14651858.CD011437.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011437.pub2&amp;doi=10.1002/14651858.CD011437.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011437.pub2&amp;doi=10.1002/14651858.CD011437.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011437.pub2&amp;doi=10.1002/14651858.CD011437.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011437.pub2&amp;doi=10.1002/14651858.CD011437.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="JmNqPX1V";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011437\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011437\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011437\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011437\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ms","hr","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011437.pub2",title:"Long\\u2010acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthma",firstPublishedDate:"Jul 21, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=JmNqPX1V&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011437.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011437.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011437.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011437.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011437.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011437.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011437.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011437.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011437.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011437.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3328 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011437.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011437.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011437.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011437.pub2/full#CD011437-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011437.pub2/full#CD011437-sec-0086"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011437.pub2/full#CD011437-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011437.pub2/full#CD011437-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011437.pub2/full#CD011437-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011437.pub2/full#CD011437-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011437.pub2/full#CD011437-sec-0053"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011437.pub2/full#CD011437-sec-0080"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011437.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011437.pub2/appendices#CD011437-sec-0091"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011437.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011437.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/table_n/CD011437StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/table_n/CD011437StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011437.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011437.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011437.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011437.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011437.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011437.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2015 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthma </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011437.pub2/information#CD011437-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>David JW Evans</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011437.pub2/information#CD011437-cr-0003">Kayleigh M Kew</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011437.pub2/information#CD011437-cr-0004">Debbie E Anderson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011437.pub2/information#CD011437-cr-0005">Anne C Boyter</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/information/en#CD011437-sec-0100">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 21 July 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011437.pub2">https://doi.org/10.1002/14651858.CD011437.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011437-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011437-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011437-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011437-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011437-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011437-abs-0001" lang="en"> <section id="CD011437-sec-0001"> <h3 class="title" id="CD011437-sec-0001">Background</h3> <p>Long‐acting muscarinic antagonists (LAMA), a class of drugs with proven effectiveness in chronic obstructive pulmonary disease (COPD), are being considered as an add‐on option for adults with asthma whose condition is uncontrolled on inhaled corticosteroids (ICS). It is important to assess the safety and efficacy of LAMA add‐on as an alternative to the prolonged use of higher doses of ICS, which are known to cause undesirable side effects in some people. </p> </section> <section id="CD011437-sec-0002"> <h3 class="title" id="CD011437-sec-0002">Objectives</h3> <p>To compare the effects of adding a LAMA to any dose of ICS versus increasing the dose of ICS, for uncontrolled asthma in adults. </p> </section> <section id="CD011437-sec-0003"> <h3 class="title" id="CD011437-sec-0003">Search methods</h3> <p>We searched the Cochrane Airways Group Specialised Register (CAGR) from its inception in 1995 to April 2015, imposing no restriction on language of publication. We also handsearched trial registries, reference lists of primary studies and existing reviews, as well as manufacturers' websites. </p> </section> <section id="CD011437-sec-0004"> <h3 class="title" id="CD011437-sec-0004">Selection criteria</h3> <p>We looked for parallel or cross‐over randomised controlled trials lasting at least 12 weeks, in which adults whose asthma was not well controlled on ICS alone were randomised to treatment with LAMA add‐on to ICS or with an increased dose of ICS. Trials were excluded if patients were taking long‐acting beta<sub>2</sub>‐agonists during the study period. </p> </section> <section id="CD011437-sec-0005"> <h3 class="title" id="CD011437-sec-0005">Data collection and analysis</h3> <p>Two review authors independently screened the searches and extracted data from studies meeting all the inclusion criteria. We used <a href="http://Covidence" target="_blank">Covidence</a> to manage duplicate screening, data extraction and risk of bias judgements, and to form a consensus where discrepancies arose. We used standard methods expected by The Cochrane Collaboration. </p> <p>The pre‐specified primary outcomes were exacerbations requiring a course of oral corticosteroids (OCS), effects on quality of life and serious adverse events. </p> </section> <section id="CD011437-sec-0006"> <h3 class="title" id="CD011437-sec-0006">Main results</h3> <p>One cross‐over randomised controlled trial met the inclusion criteria. The trial was performed in 210 patients with moderate to severe asthma and compared the use of the LAMA tiotropium bromide with double dose beclomethasone (an ICS) using a cross‐over design and 14‐week treatment periods. </p> <p>Compared with people taking a double dose of ICS, fewer people taking a LAMA add‐on had an exacerbation requiring treatment with OCS (odds ratio (OR) 0.57, 95% confidence interval (CI) 0.22 to 1.43) or an exacerbation resulting in emergency department admission (OR 0.49, 95% CI 0.09 to 2.77), but the confidence intervals for both outcomes did not exclude the possibility that double dose ICS was more effective. Serious adverse events and exacerbations requiring hospitalisation occurred in similarly low numbers of people taking each treatment, but confidence intervals were too wide to suggest that the two treatment options were equivalent. </p> <p>Asthma‐related quality of life was similar in both treatment groups (mean difference (MD) in change from baseline 0.10, 95% CI − 0.07 to 0.27). Those taking LAMA add‐on scored slightly better on a scale measuring asthma control than those increasing their ICS dose (MD in change from baseline − 0.18, 95% CI − 0.34 to − 0.02), although the difference was clinically small. Evidence was deemed low quality for both quality of life and asthma control. </p> <p>There was moderate‐quality evidence that participants' trough forced expiratory volume in one second (FEV<sub>1</sub>) was 100 mL better when taking LAMA add‐on than with increased ICS dose (MD in change from baseline 0.10, 95% CI 0.03 to 0.17). </p> </section> <section id="CD011437-sec-0007"> <h3 class="title" id="CD011437-sec-0007">Authors' conclusions</h3> <p>Only one randomised trial was found, comparing tiotropium add‐on to increased dose beclomethasone. Differences between the treatments were too small or imprecise to understand whether adding a LAMA to ICS is safer or more effective than increasing the dose of ICS, and there is a possibility of carry‐over effects due to the study's cross‐over design. LAMA add‐on may lead to more improvement in lung function (FEV<sub>1</sub>) than an increased dose of ICS. </p> <p>The results of this review, alongside pending results from related reviews assessing the use of LAMA against other treatments, will help to define the role of these drugs in asthma management, and this review should be updated as results from future trials emerge. Studies assessing the role of LAMA add‐on should be longer and include a double‐ICS treatment arm so that the results can be interpreted in the context of the guideline‐recommended treatment options that are available to physicians. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011437-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011437-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011437-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011437-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011437-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD011437-abs-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011437-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011437-abs-0005">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011437-abs-0004" lang="en"> <h3>For people with uncontrolled asthma on inhaled steroids, is it better to increase the dose or add a long‐acting muscarinic antagonist? </h3> <p>We don't yet know whether adding LAMA to ICS is better or worse than increasing the dose of ICS. It is important that future studies include a treatment group for people given a double dose of ICS, because this is an option for doctors treating people with asthma. </p> <p><b>Why is the question important?</b> </p> <p>Physicians treating patients with asthma that is not adequately controlled by inhaled corticosteroids (ICS) can either increase the dose of steroids or add another type of treatment. One type of drug that can complement ICS are long‐acting muscarinic antagonists (LAMAs), which are effective in treating other lung diseases and are starting to become available for treating asthma. Increasing the dose of ICS can cause unwanted side effects such as weakened bones, sleep problems and anxiety, so adding a LAMA to existing doses of ICS may be an effective alternative. </p> <p><b>How did we answer the question?</b> </p> <p>Two people looked for published and unpublished research in several databases and websites to find relevant studies comparing LAMA plus ICS with increased doses of ICS for asthma in adults. We analysed the results available up to April 2015 in this systematic review. </p> <p><b>What did we find?</b> </p> <p>We found one study involving 210 patients with asthma. The trial compared adding tiotropium (a LAMA) to doubling the dose of beclomethasone (a steroid). </p> <p>In the trial, people taking a combination of the LAMA and ICS were slightly less likely to have an asthma attack needing treatment with oral steroids. Our results suggest that for every 1000 people, 18 fewer in the LAMA group would need these treatments compared to patients treated with an increased dose of ICS. However, there is a relatively wide margin of error in this estimate, and the actual number of patients on LAMA who might need steroids because of an asthma attack could range from 52 fewer to 26 more people per 1000. Similarly, neither option was more clearly beneficial on any of the following measures: asthma attacks resulting in hospitalisation or admission to the emergency department, serious adverse events, control of asthma or quality of life related to asthma. On the other hand, LAMA plus ICS might improve lung function a bit more than increasing ICS dose. </p> <p>We didn't have much confidence in the findings because the one included study only looked at one type of LAMA (tiotropium) for a short period of time (14 weeks). </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011437-sec-0086" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011437-sec-0086"></div> <h3 class="title" id="CD011437-sec-0087">Implications for practice</h3> <section id="CD011437-sec-0087"> <p>Only one randomised trial was found, comparing tiotropium add‐on to increased dose beclomethasone. Differences between the treatments were generally too small or imprecise to tell whether adding a LAMA to ICS is safer or more effective than increasing the dose of ICS, and there is a possibility of carryover effects due to the study's cross‐over design. LAMA add‐on may lead to more improvement in lung function (FEV<sub>1</sub>) than increasing ICS dose. </p> </section> <h3 class="title" id="CD011437-sec-0088">Implications for research</h3> <section id="CD011437-sec-0088"> <p>The results of this review, alongside pending results from related reviews assessing the use of LAMA against other treatments, will help to define the role of these drugs in asthma and should be updated as results from future trials emerge. Studies assessing the role of LAMA add‐on should be longer and include a double‐ICS treatment arm so that the results can be interpreted in the context of the guideline‐recommended treatment options that are available to physicians. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011437-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011437-sec-0022"></div> <div class="table" id="CD011437-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">ICS + LAMA add‐on compared to ICS dose increase for adults with asthma</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>ICS + LAMA add‐on <i>versus</i> ICS dose increase for adults with asthma</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with asthma<br/> <b>Settings:</b> outpatient<br/> <b>Intervention:</b> ICS + LAMA add‐on<br/> <b>Comparison:</b> ICS dose increase </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> ICS dose increase</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> ICS + LAMA add‐on</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbations requiring a course of OCS<sup>a</sup> </p> <p>14 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>68 per 1000<sup>b</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 1000<br/> (16 to 94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.57<br/> (0.22 to 1.43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>174<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low <sup>c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No clear benefit of one treatment over the other</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AQLQ score</p> <p>(Scale 1 to 7, where 1 = severely impaired and 7 = no impairment)</p> <p>14 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in the ICS dose‐increase group was 0.15<sup>e</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline was 0.1 better in the LAMA add‐on group (0.07 worse to 0.27 better) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>c,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No clear benefit of one treatment over the other;</p> <p>MCID for AQLQ is 0.5</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAEs (all cause)</p> <p>14 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000<sup>b</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000</p> <p>(3 to 81)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.00<br/> (0.20 to 5.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>174<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No clear benefit of one treatment over the other</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbations requiring hospitalisation</p> <p>14 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000<sup>b</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000<br/> (0 to 84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.00<br/> (0.06 to 16.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>174<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No clear benefit of one treatment over the other</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbations requiring ED visit</p> <p>14 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000<sup>b</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000<br/> (2 to 60) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.49<br/> (0.09 to 2.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>174<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No clear benefit of one treatment over the other</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FEV<sub>1</sub> pre‐albuterol (L) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The change from baseline in the ICS dose‐increase group was 0.02 L<sup>e</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline was 0.1 L better in the LAMA add‐on group (0.03 better to 0.17 better) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> moderate<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Some benefit of LAMA add‐on versus ICS dose increase; MCID not well established</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ACQ score</p> <p>Scale = 0 to 6 (0 = no impairment; 6 = maximum impairment)</p> <p>14 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The change from baseline in the ICS dose‐increase group was − 0.03<sup>e</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean difference in change from baseline was − 0.18 in the LAMA add‐on group (0.34 worse to 0.02 worse) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>c,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Small benefit of LAMA add‐on over ICS dose increase; unlikely to be clinically significant (MCID = 0.5) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>ACQ</b> : Asthma Control Questionnaire; <b>AQLQ</b> : Asthma Quality of Life Questionnaire; <b>CI:</b> Confidence interval; <b>ED</b> : emergency department; <b>FEV<sub>1</sub> </b> : forced expiratory volume in one second; <b>ICS</b> : inhaled corticosteroids; <b>LAMA</b> : long‐acting muscarinic antagonist; <b>MCID</b> : minimal clinically important difference; <b>OCS</b> : oral corticosteroids; <b>OR</b> : odds ratio; <b>RCT</b> : randomised controlled trial; <b>SAE</b>: serious adverse event. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Analyses included one participant who received systemic intravenous corticosteroids only.<br/> <sup>b</sup>Assumed risk for dichotomous outcomes was based on the mean number of endpoint events in the ICS dose increase group (additional data provided by authors).<br/> <sup>c</sup>The included study only examined one drug (tiotropium) in the LAMA class, and compared it with only one type of ICS (beclomethasone). Therefore, we cannot be certain how this evidence relates to other LAMA and ICS drugs. Furthermore, the duration of each treatment period in the single included study was only 14 weeks. Therefore, this limits the likelihood of detecting rare events such as exacerbations and serious adverse events (i.e. the dichotomous outcomes). Overall, each outcome was downgraded one point for indirectness [− 1 indirectness].<br/> <sup>d</sup>Confidence intervals are wide; analysis included data from only one study [− 1 imprecision].<br/> <sup>e</sup>Assumed risk for continuous outcomes was based on the mean change from baseline in the ICS dose increase group (see table 2 in <a href="./references#CD011437-bbs2-0001" title="LaneM . Tiotropium bromide in asthma patients: an alternative to inhaled long‐acting beta‐agonists?. Journal of the Royal College of Physicians of Edinburgh2010;40(4):321‐2. NCT00565266 . Asthma Clinical Research Network (ACRN) Trial ‐ Tiotropium bromide as an alternative to increased inhaled corticosteroid in patients inadequately controlled on a lower dose of inhaled corticosteroid (TALC). http://clinicaltrials.gov/show/NCT00565266 (accessed 19 January 2015). PetersSP , BleeckerER , KunselmanSJ , IcitovicN , MooreWC , PascualR , et al. Predictors of response to tiotropium versus salmeterol in asthmatic adults. The Journal of Allergy and Clinical Immunology2013;132(5):1068‐74. PetersSP , KunselmanSJ , IcitovicN , MooreWC , PascualR , AmeredesBT , et al. Tiotropium bromide step‐up therapy for adults with uncontrolled asthma. New England Journal of Medicine2010;363(18):1715‐26. ">Peters 2010</a>).<br/> <sup>f</sup>The washout period between treatments in the included study may have been insufficient. There was some carryover effect between treatment periods relating to the number of asthma control days (this could influence a patients perception of asthma control and quality of life). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011437-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011437-sec-0023"></div> <section id="CD011437-sec-0024"> <h3 class="title" id="CD011437-sec-0024">Description of the condition</h3> <p>Asthma is a "common and potentially serious chronic disease" that causes difficulty breathing due to narrowing of the airways, thickening of the airway walls and increased mucus production (<a href="./references#CD011437-bbs2-0053" title="Global Initiative forAsthma . Global Strategy For Asthma Management And Prevention. http://www.ginasthma.org/documents/4 (accessed 22 August 2014). ">GINA 2014</a>). Asthma is recognised as a heterogeneous disease, but common symptoms include "wheezing, shortness of breath, chest tightness and cough that vary over time in their occurrence, frequency and intensity" (<a href="./references#CD011437-bbs2-0053" title="Global Initiative forAsthma . Global Strategy For Asthma Management And Prevention. http://www.ginasthma.org/documents/4 (accessed 22 August 2014). ">GINA 2014</a>). </p> <p>Around the world and particularly in low‐ and middle‐income countries, asthma is frequently undiagnosed and untreated (<a href="./references#CD011437-bbs2-0054" title="International Union Against Tuberculosis and Lung Disease. The Global Asthma Report 2014. The Global Asthma Report 2014, http://www.globalasthmareport.org (accessed 28th August 2014). ">Global Asthma Report 2014</a>), and it remains a significant cause of avoidable morbidity and mortality in developed countries such as the UK (<a href="./references#CD011437-bbs2-0067" title="Royal College of Physicians. Why Asthma Still Kills: The National Review of Asthma Deaths (NRAD) Confidential Enquiry Report. London: Royal College of Physicians, 2014. ">NRAD 2014</a>), imposing "a substantial burden on patients, their family and the community" (<a href="./references#CD011437-bbs2-0053" title="Global Initiative forAsthma . Global Strategy For Asthma Management And Prevention. http://www.ginasthma.org/documents/4 (accessed 22 August 2014). ">GINA 2014</a>). Recent estimates suggest 334 million people are affected worldwide, with among the highest direct treatment costs and indirect costs of lost productivity for non‐communicable diseases (<a href="./references#CD011437-bbs2-0054" title="International Union Against Tuberculosis and Lung Disease. The Global Asthma Report 2014. The Global Asthma Report 2014, http://www.globalasthmareport.org (accessed 28th August 2014). ">Global Asthma Report 2014</a>). Prevalence estimates vary, and changes over time have been linked to various factors including air pollution, tobacco legislation, diet and prevalence of other atopic diseases (<a href="./references#CD011437-bbs2-0038" title="AndersonHR . Prevalence of asthma. British Medical Journal2005;330:1037. ">Anderson 2005</a>). </p> <p>The two broad aims of asthma treatment are to maintain daily symptom control and prevent acute worsening of symptoms known as asthma attacks or 'exacerbations'. To achieve this, medication, usually given via an inhaler, is started at the most appropriate level based on severity and frequency of symptoms, and in accordance with treatment 'steps' laid out in guidelines (e.g. <a href="./references#CD011437-bbs2-0043" title="British Thoracic Society, Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax2014;69(Suppl. 1):i1‐i192. ">BTS 2014</a>; <a href="./references#CD011437-bbs2-0053" title="Global Initiative forAsthma . Global Strategy For Asthma Management And Prevention. http://www.ginasthma.org/documents/4 (accessed 22 August 2014). ">GINA 2014</a>). Depending on symptom control and frequency of exacerbations after treatment has commenced, therapy can be stepped up by increasing dosage or adding medications to recapture control, or 'stepped down' to maintain patients at the lowest effective level of therapy and minimise side effects. </p> </section> <section id="CD011437-sec-0025"> <h3 class="title" id="CD011437-sec-0025">Description of the intervention</h3> <p>The lowest treatment step for asthma in most guidelines is the sole use of a short‐acting bronchodilating inhaler (e.g. salbutamol) on an as‐needed basis, which is often sufficient to treat mild or intermittent symptoms. Regular use of low‐dose inhaled corticosteroids is the primary recommended preventer therapy for people with persistent asthma that is inadequately controlled with as‐needed medication alone (Step 2, <a href="./references#CD011437-bbs2-0043" title="British Thoracic Society, Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax2014;69(Suppl. 1):i1‐i192. ">BTS 2014</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1408221309418436778421379556564%26format=REVMAN#REF-GINA-2014" target="_blank">GINA 2014</a>). Regular ICS has been shown to improve lung function and reduce the need for reliever medications (<a href="./references#CD011437-bbs2-0035" title="AdamsNP , BestallJB , MaloufR , LassersonTJ , JonesPW . Beclomethasone versus placebo for chronic asthma. Cochrane Database of Systematic Reviews2005, Issue 1. [DOI: 10.1002/14651858.CD002738.pub2] ">Adams 2008a</a>; <a href="./references#CD011437-bbs2-0036" title="AdamsNP , BestallJC , LassersonTJ , JonesP , CatesCJ . Fluticasone versus placebo for chronic asthma in adults and children. Cochrane Database of Systematic Reviews2008, Issue 4. [DOI: 10.1002/14651858.CD003135.pub4] ">Adams 2008b</a>), but some people will continue to have symptoms and asthma attacks. For this group of patients, guidelines suggest a range of treatment options (step 3 and above). Long‐acting beta<sub>2</sub>‐agonists (LABA) such as formoterol and salmeterol are the current preferred add‐on therapy at step 3 (<a href="./references#CD011437-bbs2-0049" title="DucharmeFM , Ni ChroininM , GreenstoneI , LassersonTJ . Addition of long‐acting beta2‐agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database of Systematic Reviews2008, Issue 5. [DOI: 10.1002/14651858.CD005535.pub2] ">Ducharme 2008</a>; <a href="./references#CD011437-bbs2-0053" title="Global Initiative forAsthma . Global Strategy For Asthma Management And Prevention. http://www.ginasthma.org/documents/4 (accessed 22 August 2014). ">GINA 2014</a>), as they have been shown to have often small but statistically significant benefits on a range of outcomes over other treatment options such as increasing ICS dose (<a href="./references#CD011437-bbs2-0050" title="DucharmeFM , Ni ChoininM , GreenstoneI , LassersonTJ . Addition of long‐acting beta2‐agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database of Systematic Reviews2010, Issue 4. [DOI: 10.1002/14651858.CD005533.pub2] ">Ducharme 2010</a>), adding theophylline (<a href="./references#CD011437-bbs2-0072" title="TeeA , KohMS , GibsonPG , LassersonTJ , WilsonA , IrvingLB . Long‐acting beta2‐agonists versus theophylline for maintenance treatment of asthma. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD001281.pub2] ">Tee 2009</a>), or adding a leukotriene receptor antagonist (<a href="./references#CD011437-bbs2-0044" title="ChauhanBF , DucharmeFM . Addition to inhaled corticosteroids of long‐acting beta2‐agonists versus anti‐leukotrienes for chronic asthma. Cochrane Database of Systematic Reviews2014, Issue 1. [DOI: 10.1002/14651858.CD003137.pub5] ">Chauhan 2014</a>). Add‐on drugs that allow the ICS dose to be kept low are often seen as preferable since prolonged use of higher doses of ICS carries the risk of serious unwanted effects, including growth retardation in children, decreased bone density, eye disorders, sleep problems and anxiety (<a href="./references#CD011437-bbs2-0066" title="National Institute for Health and Care Excellence. NICE advice [KTT5] High‐dose inhaled corticosteroids in asthma. http://www.nice.org.uk/Advice/ktt5 (accessed 29 August 2014). ">NICE 2013</a>). </p> <p>Long‐acting muscarinic antagonists (LAMA), a class of drugs with proven effectiveness in chronic obstructive pulmonary disease (COPD) (<a href="./references#CD011437-bbs2-0060" title="KarnerC , ChongJ , PooleP . Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2014, Issue 7. [DOI: 10.1002/14651858.CD009285.pub3] ">Karner 2014</a>), are now being considered as another add‐on therapy for asthma in adults who require more than ICS alone. Tiotropium, the first and most widely used LAMA to be licenced for COPD , has demonstrated added benefits over LABA in terms of the frequency of exacerbations and hospital admissions for COPD, but not in terms of mortality or overall hospital admissions (<a href="./references#CD011437-bbs2-0046" title="ChongJ , KarnerC , PooleP . Tiotropium versus long‐acting beta‐agonists for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 9. [DOI: 10.1002/14651858.CD009157.pub2] ">Chong 2012</a>). Evidence for the safety and efficacy of aclidinium bromide and glycopyrronium bromide, two LAMA formulations that have recently been licensed for use in COPD, is also emerging (<a href="./references#CD011437-bbs2-0065" title="NiH , SoeZ , MoeS . Aclidinium bromide for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2014, Issue 9. [DOI: 10.1002/14651858.CD010509.pub2] ">Ni 2014</a>). </p> </section> <section id="CD011437-sec-0026"> <h3 class="title" id="CD011437-sec-0026">How the intervention might work</h3> <p>LAMAs block receptors of the neurotransmitter acetylcholine on airway smooth muscle, glands and nerves, preventing muscle contraction and mucus secretion (<a href="./references#CD011437-bbs2-0064" title="MoultonBC , FryerAD . Muscarinic receptor antagonists, from folklore to pharmacology; finding drugs that actually work in asthma and COPD. British Journal of Clinical Pharmacology2011;163(1):44‐52. ">Moulton 2011</a>). The action on these receptors helps to alleviate symptoms of breathlessness, coughing and wheezing that characterise asthma (<a href="./references#CD011437-bbs2-0062" title="LipworthBJ . Emerging role of long acting muscarinic antagonists for asthma. British Journal of Clinical Pharmacology2014;77(1):55‐62. ">Lipworth 2014</a>). These characteristics of LAMA, together with the overlap in pathophysiology and symptoms between asthma and COPD (<a href="./references#CD011437-bbs2-0055" title="GosensR , ZaagsmaJ , MeursH , HalaykoAJ . Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respiratory Research2006;7(1):73. ">Gosens 2006</a>), have led to their testing as an add‐on therapy for asthma in patients who do not achieve adequate control from standard‐dose ICS alone. This course of treatment has the potential advantage of avoiding prolonged exposure to higher doses of ICS. </p> <p>The most commonly reported side effect of LAMA for airways disease is dry mouth, with others including constipation, diarrhoea, cough and headache (<a href="./references#CD011437-bbs2-0041" title="Royal Pharmaceutical Society. British National Formulary (online). http://www.medicinescomplete.com. Royal Pharmaceutical Society, (accessed 27 August 2014). ">BNF</a>). All LAMAs for maintenance of airways disease are delivered via inhalers, either by powder (tiotropium bromide, usually delivered via the HandiHaler device; aclidinium bromide, via Genuair; glycopyrronium bromide, via Breezhaler) or soft mist delivery (albuterol and ipratropium combination, via Respimat) and are not suitable to be used as rescue medication. </p> <p>In COPD, there is conflicting evidence regarding the safety of tiotropium delivered via the Respimat device, with one recent observational study finding it increased the risk of death, particularly cardiac, compared with placebo via the HandiHaler device (<a href="./references#CD011437-bbs2-0073" title="VerhammeKM , AfonsoA , RomioS , StrickerBC , BrusselleGG , SturkenboomMC . Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patient with COPD. European Respiratory Journal2013;42(3):606‐15. ">Verhamme 2013</a>). Another large randomised trial including over 17,000 people with COPD found no significant differences in long‐term safety between the two devices (<a href="./references#CD011437-bbs2-0074" title="WiseRA , AnzuetoA , CottonD , DahlR , DevinsT , DisseB , et al. Tiotropium Respimat Inhaler and the risk of death in COPD. New England Journal of Medicine2013;369(16):1491‐501. ">Wise 2013</a>). As yet it is unclear whether differential safety profiles will be seen in people with asthma. </p> </section> <section id="CD011437-sec-0027"> <h3 class="title" id="CD011437-sec-0027">Why it is important to do this review</h3> <p>Tiotropium bromide (Spiriva Respimat 2.5 mcg) is the only LAMA preparation that has been granted a UK license for use in severe asthma in combination with LABA and ICS (<a href="./references#CD011437-bbs2-0052" title="Electronic Medicines Compendium(eMC) . License extension 19th September 2014: Spiriva Respimat 2.5 micrograms solution for inhalation. https://www.medicines.org.uk/emc/history/20134 (accessed 24 October 2014). ">eMC 2014</a>). Following the demonstrated efficacy of LAMAs in COPD (<a href="./references#CD011437-bbs2-0060" title="KarnerC , ChongJ , PooleP . Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2014, Issue 7. [DOI: 10.1002/14651858.CD009285.pub3] ">Karner 2014</a>), clinical trials are emerging to test the use of various LAMA regimens against the existing treatment options for asthma. One study found that nearly 30% of patients whose asthma was uncontrolled on fluticasone remained so with the guideline‐recommended addition of LABA (<a href="./references#CD011437-bbs2-0039" title="BatemanED , BousheyHA , BousquetJ , BusseWW , ClarkTJ , PauwelsRA , et al. Can guideline‐defined asthma control be achieved? The gaining optimal asthma control study. American Journal of Respiratory and Critical Care Medicine2004;170(8):836‐44. ">Bateman 2004</a>), suggesting there is a need for more options for add‐on therapy. </p> <p>It is important to assess the safety of using LAMA add‐on to ICS as an alternative to prolonged use of high doses of ICS, which are known to cause undesirable side effects (<a href="./references#CD011437-bbs2-0066" title="National Institute for Health and Care Excellence. NICE advice [KTT5] High‐dose inhaled corticosteroids in asthma. http://www.nice.org.uk/Advice/ktt5 (accessed 29 August 2014). ">NICE 2013</a>). As a complement to results from three other reviews, this review summarises the evidence to guide the possible use of LAMA add‐on as an alternative steroid‐sparing agent. The other reviews assess LAMA add‐on compared with LABA add‐on (<a href="./references#CD011437-bbs2-0061" title="KewKM , EvansDJW , AllisonDE , BoyterAC . Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long‐acting beta2‐agonists (LABA) for adults with asthma. Cochrane Database of Systematic Reviews2015, Issue 6. [DOI: 10.1002/14651858.CD011438.pub2] ">Kew 2015</a>), LAMA add‐on compared with no change to ICS dose (<a href="./references#CD011437-bbs2-0037" title="AllisonDE , KewKM , BoyterAC . Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS for adults with asthma. Cochrane Database of Systematic Reviews2014, Issue 11. [DOI: 10.1002/14651858.CD011397] ">Allison 2014</a>) and LAMA add‐on as part of a triple therapy with LABA+ICS compared with LABA+ICS alone (<a href="./references#CD011437-bbs2-0061" title="KewKM , EvansDJW , AllisonDE , BoyterAC . Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long‐acting beta2‐agonists (LABA) for adults with asthma. Cochrane Database of Systematic Reviews2015, Issue 6. [DOI: 10.1002/14651858.CD011438.pub2] ">Kew 2015</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011437-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011437-sec-0028"></div> <p>To compare the effects of adding a LAMA to any dose of ICS versus increasing the dose of ICS, for uncontrolled asthma in adults. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011437-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011437-sec-0029"></div> <section id="CD011437-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011437-sec-0031"> <h4 class="title">Types of studies</h4> <p>We included double‐blinded parallel or cross‐over randomised controlled trials (RCTs) lasting at least 12 weeks. We included studies reported as full‐text and those published as abstract only, as well as unpublished data. Because the long‐term effects of ICS may not wash out between treatments in cross‐over trials, we performed a sensitivity analysis excluding them from the primary analyses. </p> <p>We did not exclude studies on the basis of a lack of blinding.</p> </section> <section id="CD011437-sec-0032"> <h4 class="title">Types of participants</h4> <p>We included adults (at least 18 years) whose asthma was not well controlled on ICS alone. We excluded trials that included participants with other chronic respiratory comorbidities (e.g. COPD, bronchiectasis). </p> <p>If studies also included adolescents or children under 12, and data were not reported separately, we included them if the mean age in both treatment groups was over 18. </p> </section> <section id="CD011437-sec-0033"> <h4 class="title">Types of interventions</h4> <p>We included studies that randomised participants to receive any dose of the following LAMA preparations as an add‐on to any dose of ICS. </p> <p> <ul id="CD011437-list-0001"> <li> <p>Tiotropium (Spiriva Handihaler or Respimat).</p> </li> <li> <p>Aclidinium bromide (Eklira Genuair).</p> </li> <li> <p>Glycopyrronium bromide (Seebri Breezhaler).</p> </li> </ul> </p> <p>Eligible comparison group participants were randomised to receive an increase in ICS dose. </p> <p>We included studies that permitted the use of short‐acting medications, such as salbutamol or a combination of terbutaline and ipratropium, as reliever therapy. However, to assess the effect of LAMA plus ICS in isolation, we excluded trials where: </p> <p> <ul id="CD011437-list-0002"> <li> <p>a long‐acting beta<sub>2</sub>‐agonist (LABA) was given as part of the randomised treatment (i.e. LAMA+ICS+LABA vs. ICS+LABA); </p> </li> <li> <p>participants were required to be taking a LABA to be included in the trial; and</p> </li> <li> <p>the majority of participants continued treatment with LABA alongside the randomised treatment. </p> </li> </ul> </p> </section> <section id="CD011437-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD011437-sec-0035"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD011437-list-0003"> <li> <p>Exacerbations requiring oral corticosteroids</p> </li> <li> <p>Quality of life (measured on a validated asthma scale, e.g. Asthma Quality of Life Questionnaire) </p> </li> <li> <p>Serious adverse events (all causes)</p> </li> </ol> </p> </section> <section id="CD011437-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD011437-list-0004"> <li> <p>Exacerbations requiring hospitalisation</p> </li> <li> <p>Lung function (in particular, trough FEV<sub>1</sub>) </p> </li> <li> <p>Asthma control (measured on a validated scale, e.g. Asthma Control Questionnaire or Asthma Control Test) </p> </li> <li> <p>Adverse events</p> </li> </ol> </p> <p>Reporting one or more of the outcomes listed here in the trial was not an inclusion criterion for the review. </p> <p>If exacerbations were reported as a composite of more than one definition (e.g. patients with one or more exacerbations requiring hospitalisation or emergency department visit), they were analysed separately. </p> </section> </section> </section> <section id="CD011437-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011437-sec-0038"> <h4 class="title">Electronic searches</h4> <p>We identified trials from the Cochrane Airways Group Specialised Register (CAGR), which is maintained by the Trials Search Co‐ordinator for the Group. The Register contains trial reports identified through systematic searches of bibliographic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED and PsycINFO as well as through handsearching of respiratory journals and meeting abstracts (please see <a href="./appendices#CD011437-sec-0092">Appendix 1</a> for further details). We searched all records in the CAGR using the search strategy in <a href="./appendices#CD011437-sec-0098">Appendix 2</a>. The most recent search was conducted in April 2015. </p> <p>We also conducted a search of ClinicalTrials.gov (www.clinicaltrials.gov) and the WHO trials portal (www.who.int/ictrp/en/). We searched all databases from their inception to the present, with no restriction on language of publication. </p> </section> <section id="CD011437-sec-0039"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists of all primary studies and review articles for additional references. We also searched relevant manufacturers' websites for trial information. </p> <p>A search was performed on 19 Feburary 2015 for errata or retractions from included full‐text studies published on PubMed (www.ncbi.nlm.nih.gov/pubmed). </p> </section> </section> <section id="CD011437-sec-0040"> <h3 class="title" id="CD011437-sec-0040">Data collection and analysis</h3> <section id="CD011437-sec-0041"> <h4 class="title">Selection of studies</h4> <p>The titles and abstracts of all potential studies identified by the search were independently screened for inclusion by two review authors (KK and DE, using <a href="./references#CD011437-bbs2-0047" title="The Alfred Hospital, Monash University, National ICT Australia and the University of London. Covidence. Melbourne: Alfred Health, 2013. ">Covidence</a>) and coded as 'retrieve' (eligible or potentially eligible/unclear) or 'do not retrieve'. We retrieved the full‐text study reports and publications, and two review authors independently screened these to identify studies for inclusion or to identify and record reasons for the exclusion of the ineligible studies. We resolved any disagreement through discussion, or if required, we consulted a third person (DA or AB). Duplicates were identified and excluded, and multiple reports of the same study were collated so that each study (rather than each report) was the unit of interest in the review. The selection process was recorded in sufficient detail to complete a PRISMA flow diagram and '<a href="./references#CD011437-sec-0106" title="">Characteristics of included studies</a>' table. </p> </section> <section id="CD011437-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>We used a data collection form for study characteristics and outcome data, which had been piloted on a related systematic review. Two review authors (DE and KK) extracted the following characteristics from the included study. </p> <p> <ol id="CD011437-list-0005"> <li> <p>Methods: study design, total duration of study, details of any run‐in period, number of study centres and location, study setting, withdrawals and study period. </p> </li> <li> <p>Participants: Number of patients, mean age, age range, sex, severity and duration of condition, diagnostic criteria, baseline lung function, smoking history, inclusion criteria and exclusion criteria. </p> </li> <li> <p>Interventions: intervention, duration of intervention, comparison, concomitant medications and excluded medications. </p> </li> <li> <p>Outcomes: primary and secondary outcomes specified and collected, and time points reported. </p> </li> <li> <p>Notes: funding for trial and notable conflicts of interest of trial authors.</p> </li> </ol> </p> <p>Two review authors (KK and DE) independently extracted outcome data from the included study. We noted in the '<a href="./references#CD011437-sec-0106" title="">Characteristics of included studies</a>' table if outcome data were not reported in a usable way. Disagreements were resolved by consensus or by involving a third person (DA or AB). One review author (DE) transferred the data into the <a href="./references#CD011437-bbs2-0070" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan</a> file and another author double‐checked that data were entered correctly by comparing the data presented in the systematic review with the study report (KK). </p> </section> <section id="CD011437-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (DE and KK) independently assessed the risk of bias for the study using criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011437-bbs2-0057" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011</a>). We resolved any disagreements by discussion or by involving another author (DA or AB). The risk of bias was assessed according to the following domains. </p> <p> <ol id="CD011437-list-0006"> <li> <p>Random sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel.</p> </li> <li> <p>Blinding of outcome assessment.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> <li> <p>Other bias.</p> </li> </ol> </p> <p>We graded each potential source of bias as high, low or unclear and provided a quotation from the study report together with a justification for our judgment in the 'Risk of bias' table. We planned to summarise the risk of bias judgements across different studies for each of the domains listed, but there was only one included study. We considered blinding separately for different key outcomes where necessary (e.g. for unblinded outcome assessment, risk of bias for all‐cause mortality may be very different than for a patient‐reported pain scale). Where information on risk of bias related to unpublished data or correspondence with a trialist, we noted this in the 'Risk of bias' table. </p> <p>When considering treatment effects, we took into account the risk of bias for the studies that contributed to that outcome. </p> <p>We conducted the review according to the published protocol and reported any deviations in the '<a href="#CD011437-sec-0104">Differences between protocol and review</a>' section of the systematic review. </p> </section> <section id="CD011437-sec-0044"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed dichotomous data as odds ratios (ORs) and continuous data as mean difference (MD) or standardised mean difference (SMD). Data presented as a scale were entered with a consistent direction of effect. We provided a narrative description of skewed data reported as medians and interquartile ranges. We analysed data from the cross‐over trial using generic inverse variance and only if double‐counting of participants was accounted for. If raw data and adjusted analyses (e.g. accounting for baseline differences) were both presented, we used the latter. </p> <p>If more studies are identified in future updates of this review, we will perform meta‐analyses only where meaningful (i.e. if the treatments, participants and the underlying clinical question are similar enough for pooling to make sense). </p> <p>Where multiple trial arms were reported in a single trial, we included only the relevant arms. If two comparisons (e.g. drug A versus placebo and drug B versus placebo) were combined in the same meta‐analysis, we halved the control group to avoid double‐counting. </p> <p>If change from baseline and endpoint scores were available for continuous data, we used the change from baseline unless the majority of studies reported endpoint scores. If a study reported outcomes at multiple time‐points, we used the end‐of‐study measurement. </p> <p>When an analysis using only participants who completed the trial and an analysis which imputed data for participants who were randomised but did not provide endpoint data (e.g. last observation carried forward) were both available, we used the latter. </p> <p>For dichotomous outcomes, we assumed equivalence of treatments if the odds ratio estimate and its 95% confidence intervals were between the pre‐defined arbitrary limits of 0.9 and 1.1. </p> </section> <section id="CD011437-sec-0045"> <h4 class="title">Unit of analysis issues</h4> <p>For dichotomous outcomes, we used participants rather than events as the unit of analysis (i.e. number of adults admitted to hospital rather than number of admissions per adult). However, if exacerbations were reported as rate ratios we analysed them on this basis. For cross‐over trials, we requested data in the format described in <a href="./references#CD011437-bbs2-0051" title="ElbourneDR , AltmanDG , HigginsJPT , CurtinF , WorthingtonHV , VailA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a> to control for intercorrelation of matched pairs. For continuous data in cross‐over trials, we entered data using generic inverse variance from suitable adjusted analyses to account for the trial's design. </p> </section> <section id="CD011437-sec-0046"> <h4 class="title">Dealing with missing data</h4> <p>Where possible, we contacted investigators or study sponsors to verify key study characteristics and obtain missing numerical outcome data (e.g. when a study is identified as abstract only). If this was not possible, and the missing data were thought to introduce serious bias, we explored the impact of including such studies in the overall assessment of results using a sensitivity analysis. </p> </section> <section id="CD011437-sec-0047"> <h4 class="title">Assessment of heterogeneity</h4> <p>We planned to use the I² statistic to measure heterogeneity among the trials in each analysis, report if substantial heterogeneity was identified (e.g. I<sup>2</sup> greater than 30%) and explore possible causes by pre‐specified subgroup analysis. </p> </section> <section id="CD011437-sec-0048"> <h4 class="title">Assessment of reporting biases</h4> <p>We were unable to pool more than 10 trials, so it was not necessary to use a funnel plot to explore possible small study and publication biases. </p> </section> <section id="CD011437-sec-0049"> <h4 class="title">Data synthesis</h4> <p>We planned to use a random‐effects model for all analyses, as we expected variation in effects due to differences in study populations and methods. We planned to perform sensitivity analyses with a fixed‐effect model. As only one study met the inclusion criteria for this review, meta‐analyses were not performed. </p> </section> <section id="CD011437-sec-0050"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned the following subgroup analyses for the primary outcomes.</p> <p> <ol id="CD011437-list-0007"> <li> <p>Duration of therapy (≤ 6 months, &gt; 6 months).</p> </li> <li> <p>Corticosteroid dose in the control group (according to <a href="./references#CD011437-bbs2-0053" title="Global Initiative forAsthma . Global Strategy For Asthma Management And Prevention. http://www.ginasthma.org/documents/4 (accessed 22 August 2014). ">GINA 2014</a> defined low, medium and high cutoffs). </p> </li> <li> <p>Dose and type of LAMA (e.g. tiotropium Handihaler 18 mcg, tiotropium Respimat 5 mcg).</p> </li> </ol> </p> <p>We planned to use the formal test for subgroup interactions in Review Manager (<a href="./references#CD011437-bbs2-0070" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan</a>). </p> </section> <section id="CD011437-sec-0051"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform sensitivity analyses on the primary outcomes, excluding the following. </p> <p> <ol id="CD011437-list-0008"> <li> <p>Unpublished data.</p> </li> <li> <p>Studies at high risk of bias for blinding of participants and personnel.</p> </li> <li> <p>Cross‐over studies*.</p> </li> </ol> </p> <p>*There may be longer term effects of ICS that do not wash out before a subsequent treatment is started in cross‐over trials, especially at higher doses. </p> <section id="CD011437-sec-0052"> <h5 class="title">Summary of findings table</h5> <p>We created a 'Summary of findings' table (<a href="./full#CD011437-tbl-0001">summary of findings Table for the main comparison</a>) to present results for all of the named outcomes<i>.</i> We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of the evidence as it related to the data used to analyse the pre‐specified outcomes. We applied methods and recommendations described in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011437-bbs2-0057" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011</a>) using GRADEpro software (<a href="./references#CD011437-bbs2-0042" title="BrozekJ , OxmanA , SchünemannH . GradePro Version 3.2 for Windows. Hamilton (Ontario): McMaster University, 2014, 2008. ">Brozek 2008</a>), justifying all decisions to downgrade or upgrade the quality of studies using footnotes and providing comments to aid the reader's understanding of the review where necessary. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011437-sec-0053" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011437-sec-0053"></div> <section id="CD011437-sec-0054"> <h3 class="title">Description of studies</h3> <section id="CD011437-sec-0055"> <h4 class="title">Results of the search</h4> <p>We identified 58 records in the main electronic database searches, and 121 other records by searching additional resources (ClinicalTrials.gov, reference lists of other publications and drug company websites). Fifty‐nine of the total 179 records were duplicates. We screened the remaining 120, excluding 79 based on the title and abstract alone. For the remaining 41, we retrieved full texts and grouped them into 34 studies. After viewing them and resolving discrepancies, we excluded 33 studies (37 records), leaving one RCT that met all the inclusion criteria. The reasons for exclusion can be found below in the <a href="#CD011437-sec-0061">Excluded studies</a> section. We did not identify any ongoing studies, and no studies are awaiting classification. Trial flow is presented in <a href="#CD011437-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD011437-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD011437-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/image_n/nCD011437-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD011437-sec-0056"> <h4 class="title">Included studies</h4> <p>We identified one study making the comparison of interest that met the inclusion criteria (<a href="./references#CD011437-bbs2-0001" title="LaneM . Tiotropium bromide in asthma patients: an alternative to inhaled long‐acting beta‐agonists?. Journal of the Royal College of Physicians of Edinburgh2010;40(4):321‐2. NCT00565266 . Asthma Clinical Research Network (ACRN) Trial ‐ Tiotropium bromide as an alternative to increased inhaled corticosteroid in patients inadequately controlled on a lower dose of inhaled corticosteroid (TALC). http://clinicaltrials.gov/show/NCT00565266 (accessed 19 January 2015). PetersSP , BleeckerER , KunselmanSJ , IcitovicN , MooreWC , PascualR , et al. Predictors of response to tiotropium versus salmeterol in asthmatic adults. The Journal of Allergy and Clinical Immunology2013;132(5):1068‐74. PetersSP , KunselmanSJ , IcitovicN , MooreWC , PascualR , AmeredesBT , et al. Tiotropium bromide step‐up therapy for adults with uncontrolled asthma. New England Journal of Medicine2010;363(18):1715‐26. ">Peters 2010</a>). Details of study characteristics are provided in the '<a href="./references#CD011437-sec-0106" title="">Characteristics of included studies</a>' table. Briefly, 210 adult participants with asthma received tiotropium bromide (a LAMA) plus beclomethasone (an ICS); salmeterol xinaoate (LABA) plus beclomethasone, or double‐dose beclomethasone, in a randomly assigned order (three‐way cross‐over design). Only the LAMA plus ICS and double ICS groups are relevant to the present review and are considered herein. The comparison between the LAMA plus ICS and LABA plus ICS groups features in a related systematic review (<a href="./references#CD011437-bbs2-0061" title="KewKM , EvansDJW , AllisonDE , BoyterAC . Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long‐acting beta2‐agonists (LABA) for adults with asthma. Cochrane Database of Systematic Reviews2015, Issue 6. [DOI: 10.1002/14651858.CD011438.pub2] ">Kew 2015</a>). Participants had moderate to severe asthma that was inadequately controlled by a low‐dose ICS (low‐dose); patients were symptomatic (i.e. required daily controller therapy). We contacted the authors of the included study, who were able to provide additional information and analyses. </p> <section id="CD011437-sec-0057"> <h5 class="title">Design</h5> <p><a href="./references#CD011437-bbs2-0001" title="LaneM . Tiotropium bromide in asthma patients: an alternative to inhaled long‐acting beta‐agonists?. Journal of the Royal College of Physicians of Edinburgh2010;40(4):321‐2. NCT00565266 . Asthma Clinical Research Network (ACRN) Trial ‐ Tiotropium bromide as an alternative to increased inhaled corticosteroid in patients inadequately controlled on a lower dose of inhaled corticosteroid (TALC). http://clinicaltrials.gov/show/NCT00565266 (accessed 19 January 2015). PetersSP , BleeckerER , KunselmanSJ , IcitovicN , MooreWC , PascualR , et al. Predictors of response to tiotropium versus salmeterol in asthmatic adults. The Journal of Allergy and Clinical Immunology2013;132(5):1068‐74. PetersSP , KunselmanSJ , IcitovicN , MooreWC , PascualR , AmeredesBT , et al. Tiotropium bromide step‐up therapy for adults with uncontrolled asthma. New England Journal of Medicine2010;363(18):1715‐26. ">Peters 2010</a> was a three‐way, double‐blind, triple‐dummy cross‐over trial in which patients where randomised to the order in which they received each of the three treatments. The study was performed at multiple centres in the United States, and total study duration was one year, comprising a four‐week run‐in period followed by three 14‐week treatments periods, and separated by two‐week washout periods. As mentioned above, only two of the three treatment groups were relevant to this review (see below in '<a href="./references#CD011437-sec-0106" title="">Characteristics of included studies</a>' table), and data from these treatment groups contributed to the present analyses. </p> </section> <section id="CD011437-sec-0058"> <h5 class="title">Participants</h5> <p>Inclusion and exclusion criteria are listed in the '<a href="./references#CD011437-sec-0106" title="">Characteristics of included studies</a>' table. Inclusion criteria included an age of at least 18 years, a history of asthma confirmed by bronchodilator reversibility or bronchial hyperresponsiveness, a FEV<sub>1</sub> of more than 40% of the predicted value, current non‐smoking status (with a history of 10 pack‐years or less) and no requirement for additional asthma medications. Exclusion criteria included vocal cord dysfunction, respiratory tract infection, other significant medical illness, lung disease other than asthma, an asthma exacerbation within the previous four weeks, a history of life‐threatening asthma within the previous five years and pregnancy or no use of acceptable birth control methods in women of childbearing potential. </p> <p>The majority (67%) of participants were female. The mean (standard deviation, SD) age of participants was 42 (±12) years; mean body mass index was 31.4 (±8.8) kg/m<sup>2</sup> and the mean duration of asthma was 26 (±14.1) years. Mean percentage predicted FEV<sub>1</sub> before bronchodilation was 71.5% (±14.9%) at baseline. The mean (SD) Asthma Control Questionnaire (ACQ) score at baseline was 1.64 (±0.73), which is over the suggested cutoff of 1.50 to be confident of inadequately controlled asthma (<a href="./references#CD011437-bbs2-0059" title="JuniperEF , BousquetJ , AbetzL , BatemanED , GOAL Committee. Identifying 'well‐controlled' and 'not well‐controlled' asthma using the Asthma Control Questionnaire. Respiratory Medicine2006;100(4):616‐21. ">Juniper 2006</a>). Baseline Asthma Quality of Life Questionnaire (AQLQ) score was 5.43 (±1.05). </p> </section> <section id="CD011437-sec-0059"> <h5 class="title">Interventions</h5> <p>The relevant treatment comparison in the included study comprised tiotropium (Spiriva Handihaler; 18 mcg once daily) plus beclomethasone (hydrofluoroalkane metered‐dose inhaler; 80 mcg twice daily) versus a dose increase of beclomethasone (160 mcg twice daily; i.e. a double dose of the ICS). </p> </section> <section id="CD011437-sec-0060"> <h5 class="title">Outcomes</h5> <p>The authors of <a href="./references#CD011437-bbs2-0001" title="LaneM . Tiotropium bromide in asthma patients: an alternative to inhaled long‐acting beta‐agonists?. Journal of the Royal College of Physicians of Edinburgh2010;40(4):321‐2. NCT00565266 . Asthma Clinical Research Network (ACRN) Trial ‐ Tiotropium bromide as an alternative to increased inhaled corticosteroid in patients inadequately controlled on a lower dose of inhaled corticosteroid (TALC). http://clinicaltrials.gov/show/NCT00565266 (accessed 19 January 2015). PetersSP , BleeckerER , KunselmanSJ , IcitovicN , MooreWC , PascualR , et al. Predictors of response to tiotropium versus salmeterol in asthmatic adults. The Journal of Allergy and Clinical Immunology2013;132(5):1068‐74. PetersSP , KunselmanSJ , IcitovicN , MooreWC , PascualR , AmeredesBT , et al. Tiotropium bromide step‐up therapy for adults with uncontrolled asthma. New England Journal of Medicine2010;363(18):1715‐26. ">Peters 2010</a> provided additional data. Continuous data (mean difference, 95% CI) and dichotomous data (OR, 95% CI) were entered as adjusted between‐group differences to account for the trial's cross‐over design (<a href="./references#CD011437-bbs2-0051" title="ElbourneDR , AltmanDG , HigginsJPT , CurtinF , WorthingtonHV , VailA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>), so we analysed outcomes using the generic inverse variance method (<a href="./references#CD011437-bbs2-0057" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> </section> <section id="CD011437-sec-0061"> <h4 class="title">Excluded studies</h4> <p>We excluded 33 studies after viewing full texts. The main reason for exclusion was use of the wrong comparator (n=21 records), such as ICS alone (relevant to <a href="./references#CD011437-bbs2-0037" title="AllisonDE , KewKM , BoyterAC . Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS for adults with asthma. Cochrane Database of Systematic Reviews2014, Issue 11. [DOI: 10.1002/14651858.CD011397] ">Allison 2014</a>) or ICS plus LABA (<a href="./references#CD011437-bbs2-0061" title="KewKM , EvansDJW , AllisonDE , BoyterAC . Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long‐acting beta2‐agonists (LABA) for adults with asthma. Cochrane Database of Systematic Reviews2015, Issue 6. [DOI: 10.1002/14651858.CD011438.pub2] ">Kew 2015</a>). Other reasons for study exclusion included the fact that over 50% of participants were taking LABA (n=11 records), study duration was too short (i.e. less than 12 weeks; n=3 records) or the wrong intervention was used (n=1 record). Likewise, one study was an observational cohort study rather than an RCT(n=1 record). Excluded studies and reasons for exclusion are listed in the '<a href="./references#CD011437-sec-0107" title="">Characteristics of excluded studies</a>' table. </p> </section> </section> <section id="CD011437-sec-0062"> <h3 class="title">Risk of bias in included studies</h3> <p>The included study was of a high methodological quality. Where published and publicly available information was insufficient, the trial authors were able to clarify the methods used. </p> <section id="CD011437-sec-0063"> <h4 class="title">Allocation</h4> <p>The included study was rated as at low risk of bias for both allocation domains. Communication with trial authors (<a href="./references#CD011437-bbs2-0045" title="ChinchilliVM . Allocation concealment used in our trial [personal communication]. Email to: D Evans. 16 January 2015. ">Chinchilli 2015 [pers comm]</a>) confirmed that a statistical software package was used to generate the random sequence that defined the order in which treatments would be given. Specifically, a Data Coordinating Centre carried out this task and developed a web‐based system to blind allocation. When a patient had completed screening and was ready for randomisation, a study coordinator at a clinical centre entered information into the randomisation module and was notified of the appropriate blinded drug packet (prepared by the network pharmacist) for the eligible patient. </p> </section> <section id="CD011437-sec-0064"> <h4 class="title">Blinding</h4> <p>The included study had a low risk of bias for both participants and personnel as well as outcome assessor blinding. The three‐period cross‐over study was designed to be double‐blind and triple‐dummy with placebo inhalers to blind each of the drugs in each period. The clinical trial register (ClinicalTrials.gov) stated that masking was applicable to subjects, caregivers, investigators and outcome assessors. </p> </section> <section id="CD011437-sec-0065"> <h4 class="title">Incomplete outcome data</h4> <p>The included study was rated as having a low risk of attrition bias. Less than 10% of patients dropped out during each treatment period. The number of patients withdrawing due to adverse events was lower during treatment with LAMA add‐on (n=7) compared with a double dose of ICS (n=14). </p> </section> <section id="CD011437-sec-0066"> <h4 class="title">Selective reporting</h4> <p>The included study was judged to be at low risk of bias for selective reporting. The outcomes defined in the ClinicalTrials.gov registration were mostly well reported in the published manuscripts, with the exception of the secondary biomarker outcomes, which did not influence the assessment of safety or efficacy. Asthma exacerbations and serious adverse events were not reported in a way that could be analysed without potentially double‐counting participants, but the authors were able to provide the missing data. </p> </section> <section id="CD011437-sec-0067"> <h4 class="title">Other potential sources of bias</h4> <p><a href="./references#CD011437-bbs2-0001" title="LaneM . Tiotropium bromide in asthma patients: an alternative to inhaled long‐acting beta‐agonists?. Journal of the Royal College of Physicians of Edinburgh2010;40(4):321‐2. NCT00565266 . Asthma Clinical Research Network (ACRN) Trial ‐ Tiotropium bromide as an alternative to increased inhaled corticosteroid in patients inadequately controlled on a lower dose of inhaled corticosteroid (TALC). http://clinicaltrials.gov/show/NCT00565266 (accessed 19 January 2015). PetersSP , BleeckerER , KunselmanSJ , IcitovicN , MooreWC , PascualR , et al. Predictors of response to tiotropium versus salmeterol in asthmatic adults. The Journal of Allergy and Clinical Immunology2013;132(5):1068‐74. PetersSP , KunselmanSJ , IcitovicN , MooreWC , PascualR , AmeredesBT , et al. Tiotropium bromide step‐up therapy for adults with uncontrolled asthma. New England Journal of Medicine2010;363(18):1715‐26. ">Peters 2010</a> used a cross‐over design, and the washout period between treatments was two weeks. This may not have been sufficient, as the authors commented that although minimal carryover effects were observed for measures of lung function, an effect was seen for asthma control days. We considered this to be a potential source of bias. </p> </section> </section> <section id="CD011437-sec-0068"> <h3 class="title" id="CD011437-sec-0068">Effects of interventions</h3> <p>See: <a href="./full#CD011437-tbl-0001"><b>Summary of findings for the main comparison</b> ICS + LAMA add‐on compared to ICS dose increase for adults with asthma</a> </p> <p>Only one study (<a href="./references#CD011437-bbs2-0001" title="LaneM . Tiotropium bromide in asthma patients: an alternative to inhaled long‐acting beta‐agonists?. Journal of the Royal College of Physicians of Edinburgh2010;40(4):321‐2. NCT00565266 . Asthma Clinical Research Network (ACRN) Trial ‐ Tiotropium bromide as an alternative to increased inhaled corticosteroid in patients inadequately controlled on a lower dose of inhaled corticosteroid (TALC). http://clinicaltrials.gov/show/NCT00565266 (accessed 19 January 2015). PetersSP , BleeckerER , KunselmanSJ , IcitovicN , MooreWC , PascualR , et al. Predictors of response to tiotropium versus salmeterol in asthmatic adults. The Journal of Allergy and Clinical Immunology2013;132(5):1068‐74. PetersSP , KunselmanSJ , IcitovicN , MooreWC , PascualR , AmeredesBT , et al. Tiotropium bromide step‐up therapy for adults with uncontrolled asthma. New England Journal of Medicine2010;363(18):1715‐26. ">Peters 2010</a>) met the inclusion criteria for this review. As such, data from several studies could not be pooled, and no meta‐analyses were performed. As the study followed a cross‐over design, we obtained additional data from the authors to allow us to calculate between group differences for the dichotomous outcomes. For each dichotomous outcome, the analyses below were based on all patients with complete follow‐up or who had an event. The results are described below and presented in <a href="./full#CD011437-tbl-0001">summary of findings Table for the main comparison</a>. </p> <section id="CD011437-sec-0069"> <h4 class="title">Primary outcomes</h4> <section id="CD011437-sec-0070"> <h5 class="title">Exacerbations requiring oral corticosteroids</h5> <p>Fewer people taking a LAMA add‐on had an exacerbation requiring treatment with oral steroids compared with people taking double dose ICS (OR 0.57, 95% CI 0.22 to 1.43; <a href="./references#CD011437-fig-0002" title="">Analysis 1.1</a>), but the confidence intervals did not exclude the possibility that doubling ICS was better. For people taking LAMA, we estimated that 18 fewer people per 1000 would have an exacerbation requiring steroids, but the confidence intervals ranged from 52 fewer to 26 more people per 1000. The quality of the evidence was rated as low, having been downgraded once for imprecision due to wide confidence intervals and once for indirectness, as our evidence was based on a single study examining only one drug in the LAMA class, and the study lasted only 14 weeks (the results for tiotropium may not be representative of the LAMA class as a group, and the relatively short duration of treatment makes it difficult to interpret the findings for rare events, such as exacerbations or serious adverse events, in the context of long‐term use in adults). </p> </section> <section id="CD011437-sec-0071"> <h5 class="title">Quality of life</h5> <p>People treated with LAMA add‐on were not found to have a different quality of life compared with those treated with an increased dose of ICS (MD in change from baseline 0.10, 95% CI − 0.07 to 0.27; <a href="./references#CD011437-fig-0003" title="">Analysis 1.2</a>). The evidence was rated as of low quality after being downgraded once for indirectness (results may not be representative of LAMA as a class of drugs) and once due to risk of bias. We downgraded the evidence based on risk of bias because the washout period between treatments in the included study may have been too short. Indeed, a degree of carryover effect between treatment periods was observed in relation to the number of asthma control days, and this may have influenced patients' perception of quality of life as well as asthma control. </p> </section> <section id="CD011437-sec-0072"> <h5 class="title">Serious adverse event (all causes)</h5> <p>The confidence intervals were too wide to determine if there was a difference in the number of people who experienced serious adverse events (SAEs) whilst taking a LAMA add‐on compared with an increased dose of ICS (OR 1.00, 95% CI 0.20 to 5.09; <a href="./references#CD011437-fig-0004" title="">Analysis 1.3</a>). The quality of the evidence was rated as low, having been downgraded once for imprecision due to wide confidence intervals (SAEs were rare) and once for indirectness (single study with one type of LAMA and relatively short treatment duration). </p> </section> </section> <section id="CD011437-sec-0073"> <h4 class="title">Secondary outcomes</h4> <section id="CD011437-sec-0074"> <h5 class="title">Exacerbations requiring hospitalisation</h5> <p>The confidence intervals were too wide to determine if there was a difference in the number of people who experienced an exacerbation requiring hospitalisation whilst taking a LAMA add‐on versus an increased dose of ICS (OR 1.00, 95% CI 0.06 to 16.24; <a href="./references#CD011437-fig-0005" title="">Analysis 1.4</a>). The quality of the evidence was rated as low, having been downgraded once for imprecision due to wide confidence intervals (exacerbations were rare events), and once for indirectness (results may not be representative of LAMA as a class of drugs, and the treatment duration in the single included study was relatively short). </p> <p>Fewer people taking a LAMA add‐on had an exacerbation requiring admission to the emergency department compared with people taking double dose ICS (OR 0.49, 0.09 to 2.77; <a href="./references#CD011437-fig-0006" title="">Analysis 1.5</a>). The confidence intervals for this comparison excluded a significant effect: for people taking LAMA, we estimated that 12 fewer people per 1000 would have an exacerbation requiring admission to the emergency department, but the confidence intervals ranged from 21 fewer to 37 more people per 1000. The quality of the evidence was rated as low for the reasons described in the previous paragraph. </p> </section> <section id="CD011437-sec-0075"> <h5 class="title">Lung function</h5> <section id="CD011437-sec-0076"> <h6 class="title">Forced expiratory volume in one second (FEV<sub>1</sub>) </h6> <p>We pre‐specified this outcome as being our primary measure of lung function. The mean change from baseline in trough FEV<sub>1</sub> (L) was greater in people taking a LAMA‐add on compared with those taking an increased dose of ICS (MD 0.10, 95% CI 0.03 to 0.17; <a href="./references#CD011437-fig-0007" title="">Analysis 1.6</a>).The evidence was rated as of moderate quality after being downgraded once for indirectness because the results may not be representative of LAMA as a class of drugs. The post‐albuterol measurement also showed a smaller benefit of LAMA add‐on compared with increasing ICS dose (MD 0.04, 95% CI 0.01 to 0.07; <a href="./references#CD011437-fig-0008" title="">Analysis 1.7</a>). </p> </section> <section id="CD011437-sec-0077"> <h6 class="title">Peak expiratory flow (PEF)</h6> <p>The mean change from baseline in morning PEF (L/min) was greater in people taking a LAMA‐add on compared with those taking an increased dose of ICS (MD in change from baseline 25.80, 95% CI 14.40 to 37.20; <a href="./references#CD011437-fig-0009" title="">Analysis 1.8</a>). Similarly, the mean change from baseline in evening PEF was greater in people taking a LAMA add‐on (MD 35.30, 95% CI 24.60 to 46.00; <a href="./references#CD011437-fig-0010" title="">Analysis 1.9</a>). </p> </section> </section> <section id="CD011437-sec-0078"> <h5 class="title">Asthma control</h5> <p>Asthma control was found to be slightly improved in people taking a LAMA add‐on compared with those taking an increased dose of ICS (MD in change from baseline − 0.18, 95% CI − 0.34 to − 0.02; <a href="./references#CD011437-fig-0011" title="">Analysis 1.10</a>). However, the magnitude of the mean difference between treatment groups (and confidence intervals) was below the established minimal clinically important difference (MCID) of 0.5 for the ACQ. The evidence was rated as low quality after being downgraded once for indirectness (evidence may not be representative of LAMA class) and once due to a risk of bias associated with the study design (see AQLQ above). </p> </section> <section id="CD011437-sec-0079"> <h5 class="title">Adverse events</h5> <p>The published article (<a href="./references#CD011437-bbs2-0001" title="LaneM . Tiotropium bromide in asthma patients: an alternative to inhaled long‐acting beta‐agonists?. Journal of the Royal College of Physicians of Edinburgh2010;40(4):321‐2. NCT00565266 . Asthma Clinical Research Network (ACRN) Trial ‐ Tiotropium bromide as an alternative to increased inhaled corticosteroid in patients inadequately controlled on a lower dose of inhaled corticosteroid (TALC). http://clinicaltrials.gov/show/NCT00565266 (accessed 19 January 2015). PetersSP , BleeckerER , KunselmanSJ , IcitovicN , MooreWC , PascualR , et al. Predictors of response to tiotropium versus salmeterol in asthmatic adults. The Journal of Allergy and Clinical Immunology2013;132(5):1068‐74. PetersSP , KunselmanSJ , IcitovicN , MooreWC , PascualR , AmeredesBT , et al. Tiotropium bromide step‐up therapy for adults with uncontrolled asthma. New England Journal of Medicine2010;363(18):1715‐26. ">Peters 2010</a>) reports that people taking the double dose of ICS had a higher number of unscheduled visits for asthma symptoms and events for which urgent care was needed compared with people taking a LAMA. We did not obtain additional data specifically for this endpoint. However, data relating to exacerbations and serious adverse events are provided above. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011437-sec-0080" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011437-sec-0080"></div> <section id="CD011437-sec-0081"> <h3 class="title" id="CD011437-sec-0081">Summary of main results</h3> <p>One cross‐over trial met the inclusion criteria for this review. The trial was performed in 210 patients with moderate to severe asthma and compared the use of beclomethasone 80 mcg twice daily plus tiotropium bromide 18 mcg once daily (morning) with double dose (160 mcg) beclomethasone twice daily (<a href="./references#CD011437-bbs2-0001" title="LaneM . Tiotropium bromide in asthma patients: an alternative to inhaled long‐acting beta‐agonists?. Journal of the Royal College of Physicians of Edinburgh2010;40(4):321‐2. NCT00565266 . Asthma Clinical Research Network (ACRN) Trial ‐ Tiotropium bromide as an alternative to increased inhaled corticosteroid in patients inadequately controlled on a lower dose of inhaled corticosteroid (TALC). http://clinicaltrials.gov/show/NCT00565266 (accessed 19 January 2015). PetersSP , BleeckerER , KunselmanSJ , IcitovicN , MooreWC , PascualR , et al. Predictors of response to tiotropium versus salmeterol in asthmatic adults. The Journal of Allergy and Clinical Immunology2013;132(5):1068‐74. PetersSP , KunselmanSJ , IcitovicN , MooreWC , PascualR , AmeredesBT , et al. Tiotropium bromide step‐up therapy for adults with uncontrolled asthma. New England Journal of Medicine2010;363(18):1715‐26. ">Peters 2010</a>). The study was of good methodological quality and considered to be at low risk of bias for all domains except one. </p> <p>Fewer people taking a LAMA add‐on had an exacerbation requiring treatment with oral steroids compared with people taking double dose ICS, but the confidence intervals did not exclude the possibility that increased ICS dose was better: our results suggest that 18 fewer people per 1000 taking a LAMA would have an exacerbation requiring a course of OCS, but the confidence intervals ranged from 52 fewer to 26 more per 1000. Approximately equal numbers of people taking each treatment had an exacerbation requiring hospitalisation, but confidence intervals were too wide to suggest equivalence. Fewer people taking a LAMA had an exacerbation resulting in admission to an emergency department, but again the confidence intervals did not exclude benefit of an ICS dose increase. Being based on only a small number of events in a single study, the quality of evidence for all of the exacerbation‐related outcomes was rated as low. We downgraded the evidence based on imprecision and indirectness. Serious adverse events (all causes) also occurred in similarly low numbers of people taking each treatment, but the confidence intervals were too wide to conclude equivalence. Again, the evidence was downgraded to low quality due to imprecision and indirectness. </p> <p>We did not find a significant difference in asthma‐related quality of life between treatment groups. People taking a LAMA‐add on scored slightly better on a scale measuring asthma control (ACQ) compared with people taking an increased dose of ICS. The magnitude of this effect was too small to be considered clinically significant, and the evidence for both of these measures (quality of life and asthma control) was considered as low quality, having been downgraded once for imprecision and once for risk of bias. </p> <p>There was some evidence to support benefits of a LAMA add‐on on lung function over an increased dose of ICS (as assessed by trough FEV<sub>1</sub>, our prespecified measure for lung function). The quality of evidence for trough FEV<sub>1</sub> was rated as moderate, having been downgraded once for indirectness. Other measures of lung function (post‐bronchodilator FEV<sub>1</sub>, morning PEF and evening PEF) also showed a benefit of LAMA add‐on. The quality of evidence for these other measures was not assessed, as they were not pre‐specified as outcomes of interest in the review protocol. </p> </section> <section id="CD011437-sec-0082"> <h3 class="title" id="CD011437-sec-0082">Overall completeness and applicability of evidence</h3> <p>The current evidence base to address our research question is insufficient in several respects. Only one study was identified that met the inclusion criteria for this review, and no sub‐group analyses were performed. The single included study used tiotropium delivered by Handihaler, so we cannot determine if our findings are applicable to other LAMA drugs such as glycopyrronium or aclidinium. Likewise, as the included study compared LAMA with an increased dose of beclomethasone, we cannot determine if the findings are relevant to other ICS. Several other studies of LAMA add‐on have been completed or published (<a href="./references#CD011437-bbs2-0020" title="NCT01172808 . A phase III randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 and 5 µg once daily) compared with placebo and salmeterol HFA MDI (50 µg twice daily) over 24 weeks in moderate persistent asthma. http://clinicaltrials.gov/show/NCT01172808 (accessed 19 January 2015). ">NCT01172808</a>; <a href="./references#CD011437-bbs2-0031" title="RajanandhMG , NageswariAD , IlangoK . Assessment of various second‐line medications in addition to inhaled corticosteroid in asthma patients: a randomized controlled trial. Clinical and Experimental Pharmacology and Physiology2014;41(7):509‐13. ">Rajanandh 2014a</a>), but double‐dose ICS was not included as a comparison group, meaning that these studies are not fully representative of the guideline‐recommended treatment options available to clinicians (<a href="./references#CD011437-bbs2-0043" title="British Thoracic Society, Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax2014;69(Suppl. 1):i1‐i192. ">BTS 2014</a>; <a href="./references#CD011437-bbs2-0053" title="Global Initiative forAsthma . Global Strategy For Asthma Management And Prevention. http://www.ginasthma.org/documents/4 (accessed 22 August 2014). ">GINA 2014</a>). </p> <p>The included study (<a href="./references#CD011437-bbs2-0001" title="LaneM . Tiotropium bromide in asthma patients: an alternative to inhaled long‐acting beta‐agonists?. Journal of the Royal College of Physicians of Edinburgh2010;40(4):321‐2. NCT00565266 . Asthma Clinical Research Network (ACRN) Trial ‐ Tiotropium bromide as an alternative to increased inhaled corticosteroid in patients inadequately controlled on a lower dose of inhaled corticosteroid (TALC). http://clinicaltrials.gov/show/NCT00565266 (accessed 19 January 2015). PetersSP , BleeckerER , KunselmanSJ , IcitovicN , MooreWC , PascualR , et al. Predictors of response to tiotropium versus salmeterol in asthmatic adults. The Journal of Allergy and Clinical Immunology2013;132(5):1068‐74. PetersSP , KunselmanSJ , IcitovicN , MooreWC , PascualR , AmeredesBT , et al. Tiotropium bromide step‐up therapy for adults with uncontrolled asthma. New England Journal of Medicine2010;363(18):1715‐26. ">Peters 2010</a>) used a cross‐over design in which 210 participants were randomly assigned to the order in which they received three treatments, each for 14 weeks (only two treatment periods were relevant to this review). The duration of the washout periods between treatment regimens was relatively short (14 days). Studies in patients with asthma have shown that ICS can have prolonged effects (<a href="./references#CD011437-bbs2-0056" title="HaahtelaT , JärvinenM , KavaT , KivirantaK , KoskinenS , LehtonenK , et al. Effects of reducing or discontinuing inhaled budesonide inpatients with mild asthma. New England Journal of Medicine1994;331(11):700‐5. ">Haahtela 1994</a>; <a href="./references#CD011437-bbs2-0058" title="JuniperEF , KlinePA , VanzieleghemMA , HargreaveFE . Reduction of budesonide after a year of increased use: a randomized controlled trial to evaluate whether improvements in airway responsiveness and clinical asthma are maintained. The Journal of Allergy and Clinical Immunology1991;87(2):483‐9. ">Juniper 1991</a>) for up to several weeks after treatment cessation (<a href="./references#CD011437-bbs2-0048" title="DeBlicJ , DelacourtC , LeBourgeoisM , MahutB , OstinelliJ , CaswellC , et al. Efficacy of nebulized budesonide in treatment of severe infantile asthma: a double‐blind study. The Journal of Allergy and Clinical Immunology1996;98(1):14‐20. ">De Blic 1996</a>). Thus, in the cross‐over study reported by Peters and colleagues, carryover effects could have confounded the results from the tiotropium treatment period if patients were randomised to receive the higher dose of ICS first. Indeed, a degree of carryover effect appeared to affect the results relating to the number of asthma control days and could have had an impact on the magnitude of difference for the other outcomes we assessed. The duration of treatment in the included study was also relatively short. Therefore, we would urge a cautious interpretation of our findings in the context of the medium‐ to long‐term use of LAMA plus ICS, particularly in terms of safety. </p> <p>The use of LAMA for asthma is relatively new, with only one UK licence extension for Spiriva Respimat to be used in combination with LABA plus ICS for patients with asthma. We anticipate that the evidence base for this topic will grow as more products are approved for this indication. Thus, we hope that the applicability of findings from future versions of this review will broaden. </p> </section> <section id="CD011437-sec-0083"> <h3 class="title" id="CD011437-sec-0083">Quality of the evidence</h3> <p>The quality of the evidence relating to two of our primary outcomes, exacerbations and serious adverse events, was rated as low. This was because only one study was included in this review and therefore the evidence is based on findings for only one member of the LAMA class (tiotropium) and may not be representative of the class as a whole. Additionally, the duration of each treatment period in the included study was only 14 weeks, so the evidence relating to exacerbations and serious adverse events (i.e. relatively rare events) cannot be considered representative of the long‐term use of these drugs. </p> <p>The quality of evidence for quality of life and asthma control was also considered to be low, having been downgraded for indirectness and also risk of bias due to evidence of a carryover effect between treatment periods in the included study, which used a cross‐over design. </p> <p>The evidence for lung function (using trough FEV<sub>1</sub>) was graded as moderate. This decision was based on a single downgrade for indirectness as discussed above. Notably, the data were extracted from a cross‐over trial where each participant acted as their own control, hence increasing the power of the study relative to a study of parallel design and similar size. Although we pre‐specified FEV<sub>1</sub> as the primary measure of lung function, other measures of lung function (PEF and post‐bronchodilator FEV<sub>1</sub>) were not pre‐specified and consequently not assessed for quality of evidence. The lack of well‐established, minimally important differences for lung function measures made it difficult to interpret the clinical significance of the magnitude and precision of the difference between LAMA add‐on and increased dose ICS. A change of approximately 10% from baseline in FEV<sub>1</sub> was reported as the MCID for asthma patients, although this was based on patient perception of change and is not well established (<a href="./references#CD011437-bbs2-0069" title="ReddelHK , TaylorDR , BatemanED , BouletLP , BousheyHA , BusseWW , et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med2009;180(1):59‐99. ">Reddel 2009</a>). Using this threshold in relation to the participants' baseline pre‐albuterol FEV<sub>1</sub>, 100 mL would not be considered clinically important, but changes in morning and evening PEF were above a reported MCID of 18.8L/min (<a href="./references#CD011437-bbs2-0069" title="ReddelHK , TaylorDR , BatemanED , BouletLP , BousheyHA , BusseWW , et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med2009;180(1):59‐99. ">Reddel 2009</a>). </p> </section> <section id="CD011437-sec-0084"> <h3 class="title" id="CD011437-sec-0084">Potential biases in the review process</h3> <p>The review was conducted to the standards set by <a href="./references#CD011437-bbs2-0063" title="ChandlerJ , ChurchillR , HigginsJ , LassersonT , ToveyD . Methodological Expectations for the conduct of Cochrane Intervention Review, version 2.3. http://editorial‐unit.cochrane.org/mecir. (accessed 3rd Feb 2015). ">MECIR 2013</a> and in accordance with the published protocol (<a href="./references#CD011437-bbs2-0075" title="KewKM , AllisonDE , EvansDJW , BoyterAC . Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthma. Cochrane Database of Systematic Reviews2014, Issue 12. [DOI: 10.1002/14651858.CD011437] ">Kew 2014</a>). There were several deviations from the protocol (see <a href="#CD011437-sec-0104">Differences between protocol and review</a>), the majority of which arose due to the inclusion of a single study in the review. </p> <p>It is unlikely that any relevant studies were missed, as a skilled information specialist conducted the main electronic searches. Additionally, the main searches were supplemented by extensive searches of several other sources (pharmaceutical company clinical trial registries and reference lists of associated studies and reviews) in addition to those required by <a href="./references#CD011437-bbs2-0063" title="ChandlerJ , ChurchillR , HigginsJ , LassersonT , ToveyD . Methodological Expectations for the conduct of Cochrane Intervention Review, version 2.3. http://editorial‐unit.cochrane.org/mecir. (accessed 3rd Feb 2015). ">MECIR 2013</a> (i.e. ClinicalTrials.gov, WHO trials portal). We also contacted the authors of the included study, who provided all requested additional or missing data and study information that was not available in the published report. </p> </section> <section id="CD011437-sec-0085"> <h3 class="title" id="CD011437-sec-0085">Agreements and disagreements with other studies or reviews</h3> <p>Several other systematic reviews have considered the use of LAMA for asthma (<a href="./references#CD011437-bbs2-0040" title="BefekaduE , OnofreiC , ColiceGL . Tiotropium in asthma: a systematic review. Journal of Asthma and Allergy2014;7:11‐21. ">Befakadu 2014</a>; <a href="./references#CD011437-bbs2-0068" title="RashidQ , KleinR . Tiotropium in the treatment of patients with asthma. Southern Medical Journal2014;107(5):330‐7. ">Rashid 2014</a>; <a href="./references#CD011437-bbs2-0071" title="RodrigoGJ , Castro‐RodríguezJA . What is the role of tiotropium in asthma?: A systematic review with meta‐analysis. Chest2015;147(2):388‐96. ">Rodrigo 2015</a>) but only Befakadu compared the LAMA versus increased dose of ICS (without LABA). Their narrative synthesis for the LAMA versus double‐ICS comparison was also based on the single study by <a href="./references#CD011437-bbs2-0001" title="LaneM . Tiotropium bromide in asthma patients: an alternative to inhaled long‐acting beta‐agonists?. Journal of the Royal College of Physicians of Edinburgh2010;40(4):321‐2. NCT00565266 . Asthma Clinical Research Network (ACRN) Trial ‐ Tiotropium bromide as an alternative to increased inhaled corticosteroid in patients inadequately controlled on a lower dose of inhaled corticosteroid (TALC). http://clinicaltrials.gov/show/NCT00565266 (accessed 19 January 2015). PetersSP , BleeckerER , KunselmanSJ , IcitovicN , MooreWC , PascualR , et al. Predictors of response to tiotropium versus salmeterol in asthmatic adults. The Journal of Allergy and Clinical Immunology2013;132(5):1068‐74. PetersSP , KunselmanSJ , IcitovicN , MooreWC , PascualR , AmeredesBT , et al. Tiotropium bromide step‐up therapy for adults with uncontrolled asthma. New England Journal of Medicine2010;363(18):1715‐26. ">Peters 2010</a>. The authors noted that tiotropium was superior to doubling the dose of ICS, but this was based on the primary outcome of the study, morning peak expiratory flow, which we did not consider as the primary measure of lung function in this review. Befakadu and colleagues also noted evidence of improved lung function in patients taking LAMA plus ICS compared with those taking increased doses of ICS; the authors concluded that it remains to be seen whether the lung function improvements will result in long‐term symptom improvement. These findings are generally in line with those of this review. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011437-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/urn:x-wiley:14651858:media:CD011437:CD011437-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/image_t/tCD011437-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD011437-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/image_n/nCD011437-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/full#CD011437-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/image_n/nCD011437-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011437-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/urn:x-wiley:14651858:media:CD011437:CD011437-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/image_t/tCD011437-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ICS + LAMA add‐on vs. ICS dose increase, Outcome 1 Exacerbations requiring a course of OCS." data-id="CD011437-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/image_n/nCD011437-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 ICS + LAMA add‐on <i>vs.</i> ICS dose increase, Outcome 1 Exacerbations requiring a course of OCS. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/references#CD011437-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/image_n/nCD011437-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011437-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/urn:x-wiley:14651858:media:CD011437:CD011437-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/image_t/tCD011437-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ICS + LAMA add‐on vs. ICS dose increase, Outcome 2 Asthma QoL questionnaire score." data-id="CD011437-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/image_n/nCD011437-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 ICS + LAMA add‐on <i>vs.</i> ICS dose increase, Outcome 2 Asthma QoL questionnaire score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/references#CD011437-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/image_n/nCD011437-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011437-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/urn:x-wiley:14651858:media:CD011437:CD011437-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/image_t/tCD011437-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ICS + LAMA add‐on vs. ICS dose increase, Outcome 3 SAEs (all cause)." data-id="CD011437-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/image_n/nCD011437-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 ICS + LAMA add‐on <i>vs.</i> ICS dose increase, Outcome 3 SAEs (all cause). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/references#CD011437-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/image_n/nCD011437-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011437-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/urn:x-wiley:14651858:media:CD011437:CD011437-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/image_t/tCD011437-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ICS + LAMA add‐on vs. ICS dose increase, Outcome 4 Exacerbations (hospital)." data-id="CD011437-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/image_n/nCD011437-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 ICS + LAMA add‐on <i>vs.</i> ICS dose increase, Outcome 4 Exacerbations (hospital). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/references#CD011437-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/image_n/nCD011437-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011437-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/urn:x-wiley:14651858:media:CD011437:CD011437-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/image_t/tCD011437-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ICS + LAMA add‐on vs. ICS dose increase, Outcome 5 Exacerbations (ED)." data-id="CD011437-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/image_n/nCD011437-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 ICS + LAMA add‐on <i>vs.</i> ICS dose increase, Outcome 5 Exacerbations (ED). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/references#CD011437-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/image_n/nCD011437-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011437-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/urn:x-wiley:14651858:media:CD011437:CD011437-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/image_t/tCD011437-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ICS + LAMA add‐on vs. ICS dose increase, Outcome 6 FEV1 pre‐albuterol (L)." data-id="CD011437-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/image_n/nCD011437-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 ICS + LAMA add‐on <i>vs.</i> ICS dose increase, Outcome 6 FEV1 pre‐albuterol (L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/references#CD011437-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/image_n/nCD011437-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011437-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/urn:x-wiley:14651858:media:CD011437:CD011437-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/image_t/tCD011437-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ICS + LAMA add‐on vs. ICS dose increase, Outcome 7 FEV1 post‐albuterol (L)." data-id="CD011437-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/image_n/nCD011437-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 ICS + LAMA add‐on <i>vs.</i> ICS dose increase, Outcome 7 FEV1 post‐albuterol (L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/references#CD011437-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/image_n/nCD011437-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011437-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/urn:x-wiley:14651858:media:CD011437:CD011437-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/image_t/tCD011437-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ICS + LAMA add‐on vs. ICS dose increase, Outcome 8 Morning PEF (L/min)." data-id="CD011437-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/image_n/nCD011437-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 ICS + LAMA add‐on <i>vs.</i> ICS dose increase, Outcome 8 Morning PEF (L/min). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/references#CD011437-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/image_n/nCD011437-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011437-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/urn:x-wiley:14651858:media:CD011437:CD011437-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/image_t/tCD011437-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ICS + LAMA add‐on vs. ICS dose increase, Outcome 9 Evening PEF (L/min)." data-id="CD011437-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/image_n/nCD011437-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 ICS + LAMA add‐on <i>vs.</i> ICS dose increase, Outcome 9 Evening PEF (L/min). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/references#CD011437-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/image_n/nCD011437-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011437-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/urn:x-wiley:14651858:media:CD011437:CD011437-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/image_t/tCD011437-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ICS + LAMA add‐on vs. ICS dose increase, Outcome 10 Asthma Control Questionnaire score." data-id="CD011437-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/image_n/nCD011437-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 ICS + LAMA add‐on <i>vs.</i> ICS dose increase, Outcome 10 Asthma Control Questionnaire score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/references#CD011437-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/media/CDSR/CD011437/image_n/nCD011437-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011437-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">ICS + LAMA add‐on compared to ICS dose increase for adults with asthma</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>ICS + LAMA add‐on <i>versus</i> ICS dose increase for adults with asthma</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with asthma<br/> <b>Settings:</b> outpatient<br/> <b>Intervention:</b> ICS + LAMA add‐on<br/> <b>Comparison:</b> ICS dose increase </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> ICS dose increase</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> ICS + LAMA add‐on</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbations requiring a course of OCS<sup>a</sup> </p> <p>14 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>68 per 1000<sup>b</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 1000<br/> (16 to 94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.57<br/> (0.22 to 1.43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>174<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low <sup>c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No clear benefit of one treatment over the other</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AQLQ score</p> <p>(Scale 1 to 7, where 1 = severely impaired and 7 = no impairment)</p> <p>14 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in the ICS dose‐increase group was 0.15<sup>e</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline was 0.1 better in the LAMA add‐on group (0.07 worse to 0.27 better) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>c,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No clear benefit of one treatment over the other;</p> <p>MCID for AQLQ is 0.5</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SAEs (all cause)</p> <p>14 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000<sup>b</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000</p> <p>(3 to 81)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.00<br/> (0.20 to 5.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>174<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No clear benefit of one treatment over the other</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbations requiring hospitalisation</p> <p>14 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000<sup>b</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000<br/> (0 to 84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.00<br/> (0.06 to 16.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>174<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No clear benefit of one treatment over the other</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbations requiring ED visit</p> <p>14 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000<sup>b</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000<br/> (2 to 60) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.49<br/> (0.09 to 2.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>174<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No clear benefit of one treatment over the other</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FEV<sub>1</sub> pre‐albuterol (L) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The change from baseline in the ICS dose‐increase group was 0.02 L<sup>e</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline was 0.1 L better in the LAMA add‐on group (0.03 better to 0.17 better) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> moderate<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Some benefit of LAMA add‐on versus ICS dose increase; MCID not well established</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ACQ score</p> <p>Scale = 0 to 6 (0 = no impairment; 6 = maximum impairment)</p> <p>14 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The change from baseline in the ICS dose‐increase group was − 0.03<sup>e</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean difference in change from baseline was − 0.18 in the LAMA add‐on group (0.34 worse to 0.02 worse) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>c,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Small benefit of LAMA add‐on over ICS dose increase; unlikely to be clinically significant (MCID = 0.5) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>ACQ</b> : Asthma Control Questionnaire; <b>AQLQ</b> : Asthma Quality of Life Questionnaire; <b>CI:</b> Confidence interval; <b>ED</b> : emergency department; <b>FEV<sub>1</sub> </b> : forced expiratory volume in one second; <b>ICS</b> : inhaled corticosteroids; <b>LAMA</b> : long‐acting muscarinic antagonist; <b>MCID</b> : minimal clinically important difference; <b>OCS</b> : oral corticosteroids; <b>OR</b> : odds ratio; <b>RCT</b> : randomised controlled trial; <b>SAE</b>: serious adverse event. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Analyses included one participant who received systemic intravenous corticosteroids only.<br/> <sup>b</sup>Assumed risk for dichotomous outcomes was based on the mean number of endpoint events in the ICS dose increase group (additional data provided by authors).<br/> <sup>c</sup>The included study only examined one drug (tiotropium) in the LAMA class, and compared it with only one type of ICS (beclomethasone). Therefore, we cannot be certain how this evidence relates to other LAMA and ICS drugs. Furthermore, the duration of each treatment period in the single included study was only 14 weeks. Therefore, this limits the likelihood of detecting rare events such as exacerbations and serious adverse events (i.e. the dichotomous outcomes). Overall, each outcome was downgraded one point for indirectness [− 1 indirectness].<br/> <sup>d</sup>Confidence intervals are wide; analysis included data from only one study [− 1 imprecision].<br/> <sup>e</sup>Assumed risk for continuous outcomes was based on the mean change from baseline in the ICS dose increase group (see table 2 in <a href="./references#CD011437-bbs2-0001" title="LaneM . Tiotropium bromide in asthma patients: an alternative to inhaled long‐acting beta‐agonists?. Journal of the Royal College of Physicians of Edinburgh2010;40(4):321‐2. NCT00565266 . Asthma Clinical Research Network (ACRN) Trial ‐ Tiotropium bromide as an alternative to increased inhaled corticosteroid in patients inadequately controlled on a lower dose of inhaled corticosteroid (TALC). http://clinicaltrials.gov/show/NCT00565266 (accessed 19 January 2015). PetersSP , BleeckerER , KunselmanSJ , IcitovicN , MooreWC , PascualR , et al. Predictors of response to tiotropium versus salmeterol in asthmatic adults. The Journal of Allergy and Clinical Immunology2013;132(5):1068‐74. PetersSP , KunselmanSJ , IcitovicN , MooreWC , PascualR , AmeredesBT , et al. Tiotropium bromide step‐up therapy for adults with uncontrolled asthma. New England Journal of Medicine2010;363(18):1715‐26. ">Peters 2010</a>).<br/> <sup>f</sup>The washout period between treatments in the included study may have been insufficient. There was some carryover effect between treatment periods relating to the number of asthma control days (this could influence a patients perception of asthma control and quality of life). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">ICS + LAMA add‐on compared to ICS dose increase for adults with asthma</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/full#CD011437-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011437-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">ICS + LAMA add‐on vs. ICS dose increase</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Exacerbations requiring a course of OCS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Asthma QoL questionnaire score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 SAEs (all cause) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Exacerbations (hospital) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Exacerbations (ED) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 FEV1 pre‐albuterol (L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 FEV1 post‐albuterol (L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Morning PEF (L/min) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Evening PEF (L/min) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Asthma Control Questionnaire score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">ICS + LAMA add‐on vs. ICS dose increase</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011437.pub2/references#CD011437-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011437.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011437-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011437-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011437-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD011437-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD011437-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD011437-note-0001">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011437\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011437\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011437\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011437\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011437\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011437\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011437\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011437\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011437\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011437\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011437\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011437\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011437\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011437\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011437\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011437\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011437\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011437\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=JmNqPX1V&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011437.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011437.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011437.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011437.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011437.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716082337"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011437.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716082341"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011437.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d96d0caf4f409',t:'MTc0MDcxNjA4Mi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 